Efficacy, tolerability, and manageability of TAS-102 plus bevacizumab for metastatic colorectal cancer patients in clinical practice.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e15535
Abstract: e15535Background: The C-TASK FORCE trial demonstrated that TAS-102 plus bevacizumab might become a potential treatment option for patients with metastatic colorectal cancer (mCRC) in a refractory s... read more here.
Keywords: 102 plus; metastatic colorectal; colorectal cancer; tas 102 ... See more keywords